Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Reducing gene expression in the brain via antisense methods.

Ouagazzal AM, Tepper JM, Creese I.

Curr Protoc Neurosci. 2001 May;Chapter 5:Unit 5.4. doi: 10.1002/0471142301.ns0504s00.

PMID:
18428503
2.

Intra-accumbens infusion of D(3) receptor agonists reduces spontaneous and dopamine-induced locomotion.

Ouagazzal AM, Creese I.

Pharmacol Biochem Behav. 2000 Nov;67(3):637-45.

PMID:
11164096
3.
4.

Effects of chronic treatment with typical and atypical antipsychotic drugs on the rat striatum.

Lee H, Tarazi FI, Chakos M, Wu H, Redmond M, Alvir JM, Kinon BJ, Bilder R, Creese I, Lieberman JA.

Life Sci. 1999;64(18):1595-602.

PMID:
10328519
5.

Antisense knockdown of brain dopamine receptors.

Creese I, Tepper JM.

Adv Pharmacol. 1998;42:517-20. No abstract available.

PMID:
9327954
6.

GTP regulation of (-)-stepholidine binding to R(H) of D1 dopamine receptors in calf striatum.

Dong ZJ, Chen LJ, Jin GZ, Creese I.

Biochem Pharmacol. 1997 Jul 15;54(2):227-32.

PMID:
9271326
7.
8.
9.
10.

Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs.

Florijn WJ, Tarazi FI, Creese I.

J Pharmacol Exp Ther. 1997 Feb;280(2):561-9.

PMID:
9023264
11.
12.

Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Creese I, Burt DR, Snyder SH.

J Neuropsychiatry Clin Neurosci. 1996 Spring;8(2):223-6.

PMID:
9081563
14.

Reduction in muscarinic receptors by antisense oligodeoxynucleotide.

Zang Z, Florijn W, Creese I.

Biochem Pharmacol. 1994 Jul 19;48(2):225-8.

PMID:
8053918
15.

Systemic 3-nitropropionic acid: long-term effects on locomotor behavior.

Koutouzis TK, Borlongan CV, Scorcia T, Creese I, Cahill DW, Freeman TB, Sanberg PR.

Brain Res. 1994 May 23;646(2):242-6.

PMID:
8069670
16.

Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates.

Zhang M, Creese I.

Neurosci Lett. 1993 Oct 29;161(2):223-6.

PMID:
7903803
17.

Expression of rat striatal D1 and D2 dopamine receptor mRNAs: ontogenetic and pharmacological studies.

Creese I, Sibley DR, Xu SX.

Neurochem Int. 1992 Mar;20 Suppl:45S-48S.

PMID:
1365454
18.

Effect of chronic nicotine treatment and withdrawal on rat striatal D1 and D2 dopamine receptors.

Kirch DG, Taylor TR, Creese I, Xu SX, Wyatt RJ.

J Pharm Pharmacol. 1992 Feb;44(2):89-92.

PMID:
1352822
19.

Regulation of D1A and D2 dopamine receptor mRNA during ontogenesis, lesion and chronic antagonist treatment.

Xu SX, Monsma FJ Jr, Sibley DR, Creese I.

Life Sci. 1992;50(5):383-96.

PMID:
1732708
20.
21.

N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain.

Xu SX, Hatada Y, Black LE, Creese I, Sibley DR.

J Pharmacol Exp Ther. 1991 May;257(2):608-15.

PMID:
1674530
22.

Lack of effect of chronic dopamine receptor blockade on D2 dopamine receptor mRNA level.

van Tol HH, Riva M, Civelli O, Creese I.

Neurosci Lett. 1990 Apr 6;111(3):303-8.

PMID:
1970862
23.
25.

Irreversible and quaternary muscarinic antagonists discriminate multiple muscarinic receptor binding sites in rat brain.

Norman AB, Eubanks JH, Creese I.

J Pharmacol Exp Ther. 1989 Mar;248(3):1116-22.

PMID:
2703964
27.

Age-related differential recovery rates of rat striatal D-1 dopamine receptors following irreversible inactivation.

Battaglia G, Norman AB, Creese I.

Eur J Pharmacol. 1988 Jan 19;145(3):281-90.

PMID:
2895004
28.

Neurochemistry and neuropharmacology.

Friedhoff AJ, Pickar D, Axelrod J, Creese I, Davis KL, Gallagher DW, Greengard P, Housman D, Maas JW, Richelson E, et al.

Schizophr Bull. 1988;14(3):399-412. No abstract available.

PMID:
2905525
30.

The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat.

Koob GF, Le HT, Creese I.

Neurosci Lett. 1987 Aug 31;79(3):315-20.

PMID:
2958724
32.

Dopamine receptor subtype imbalance in schizophrenia.

Hess EJ, Bracha HS, Kleinman JE, Creese I.

Life Sci. 1987 Apr 13;40(15):1487-97.

PMID:
2951573
33.
34.

"Selective" D-1 and D-2 receptor antagonists fail to differentially alter supersensitive locomotor behavior in the rat.

Amalric M, Koob GF, Creese I, Swerdlow NR.

Life Sci. 1986 Nov 24;39(21):1985-93.

PMID:
2946915
35.
39.
40.
41.

Guanine nucleotide regulation of agonist interactions at [3H]SCH23390-labeled D1 dopamine receptors in rat striatum.

Hess EJ, Battaglia G, Norman AB, Iorio LC, Creese I.

Eur J Pharmacol. 1986 Feb 11;121(1):31-8.

PMID:
2869957
43.

Regulation of putative muscarinic cholinergic receptor subtypes in rat brain.

Norman AB, Battaglia G, Creese I.

Neurochem Int. 1986;9(2):337-47.

PMID:
20493134
44.

Modulation of alpha-1 adrenergic receptors in rat brain following chronic reserpine.

Morrow AL, Chen AD, Creese I.

Neurochem Int. 1986;8(2):243-7.

PMID:
20493053
45.

Biochemical characteristics of D1 dopamine receptors: relationship to behavior and schizophrenia.

Creese I, Hess EJ.

Clin Neuropharmacol. 1986;9 Suppl 4:14-6. No abstract available.

PMID:
2882838
46.

Biochemical and behavioral studies of D1 dopamine receptors utilizing SCH 23390.

Hess EJ, Creese I.

Psychopharmacol Bull. 1986;22(3):605-12. No abstract available.

PMID:
2879304
47.

Biochemical and behavioral studies of D1 dopamine receptors utilizing SCH 23390.

Hess EJ, Creese I.

Adv Exp Med Biol. 1986;204:29-52. Review. No abstract available.

PMID:
2878579
48.
49.
50.

D2 dopamine receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in rat striatum.

Battaglia G, Norman AB, Hess EJ, Creese I.

Neurosci Lett. 1985 Aug 30;59(2):177-82.

PMID:
2932659

Supplemental Content

Loading ...
Support Center